The results of a placebo-controlled trial showed that apabetalone does not decrease cardiovascular (CV) death, non-fatal myocardial infarction (MI), or non-fatal stroke in diabetic patients with recent acute coronary syndrome (ACS).
Prof. Kausik K. Ray (Imperial College London, United Kingdom) presented the results of the phase 3, international, multicentre, randomised, double-blind, placebo-controlled BETonMACE trial. This study aimed to determine whether modulating epigenetics with the selective bromodomain and extra-terminal (BET) protein inhibitor apabetalone is safe and effective in reducing CV risk . Patients with type 2 diabetes mellitus, ACS within the preceding 7-90 days, and low HDL-C (≤40 mg/dl for men and ≤45 mg/dl for women) were randomised to receive either apabetalone (100 mg orally, twice a day; n=1,212) or matched placebo (n=1,206) in addition to standard-of-care therapy, e.g...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« PARAGON-HF: Benefits for women and lower ejection fraction Next Article
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI »
Table of Contents: AHA 2019
New Approaches to CVD Risk Reduction
Interventional Management for Acute Coronary Syndrome
Results for the Ischemia Trials: To Intervene or Not to Intervene
Controversies in Contemporary Management of Aortic Stenosis
Guidelines: Updates and Controversies
Trials in Electrophysiology and Left Ventricular Function
New Frontiers in Lipid Therapy
Challenges in Heart Failure Management
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.